





 J.A., an 18-month old male, presented to UNC Pediatric GI Clinic with acute febrile 
illness. During his illness, J.A loss significant weight and became generally disinterested 
in eating.  His parents reported that J.A. began to pat his chest and whine and 
occasionally would throw up after eating a few bites of food. J.A. was initially diagnosed 
with hypoalbuminemia, failure to thrive (FTT), and feeding difficulties. His severe illness 
resulted in hospitalization and thorough testing to determine the source of his symptoms. 
Endoscopy during hospital admission demonstrated findings consistent with severe 
esophageal eosinophilia. He was diagnosed with Eosinophilic Esophagitis (EoE) and 
protein losing enteropathy with a likely secondary immunodeficiency.  
 This case study serves to increase awareness of EoE, a newly appreciated 
disorder in an area of research that is only recently developing and is continuing to grow. 
We will define EoE, its etiology, symptoms, and diagnostic criteria. We will discuss the 
nutrition implications and therapy options in children with EoE. J.A., who matched 
classical presentation and achieved good control of his disease after closely following 
treatment guidelines, will serve as a model case of EoE. Physicians, dietitians, and other 
medical professionals should be aware of the increasing prevalence of EoE, know what 
to look for in its presentation, and keep up to date on the growing field of research as 
new therapies are being developed. 
 
Introduction 
What is Eosinophilic Esophagitis? 
  
 
 Eosinophilic Esophagitis (EoE) is a chronic, immune/antigen-mediated disease that 
is characterized by and must be diagnosed both clinically and histologically. EoE is 
distinguished clinically by symptoms related to esophageal dysfunction and histologically 
by eosinophil-predominant inflammation (Liacouras et. al, 2011). The presence of 
eosinophils in the gastrointestinal (GI) tract is associated with intestinal inflammatory 
disorders including eosinophilic gastroenteritis, inflammatory bowel disease, parasitic 
infections, and reflux related disorders. In normal and healthy persons, eosinophils are 
found in small numbers in all portions of the gastrointestinal tract except for in the 
esophagus. Thus, the presence of esophageal intraepithelial eosinphils is used as 
defining criteria of EoE (Liacouras, 2007).  
 The etiology of EoE is thus far not completely understood. Symptoms of EoE 
appear to be caused by an abnormal immunologic response to specific food antigens 
(Liacouras, 2007). Additionally, studies are citing seasonal symptoms of EoE, which 
suggests aeroallergens may play a role in inducing esophageal eosinophilia. A 
retrospective study show that seasonal levels of tree and grass pollen directly correlate 
with the number of patients diagnosed with EoE. Studies are needed to further examine 
the possible correlation between seasonal variability in symptoms and pollen sensitivity. 
There also appears to be genetic susceptibility and familial occurrence, but a gene has 
not been identified (Liacouras et. al, 2011). Further research is needed to identify 
specific risk factors associated with EoE. Knowledge of these risk factors will lead to a 
better understanding of the etiology of EoE and may ultimately lead to improved 
identification and treatment of the disorder (Delgado et. al, 2011). As more cases are 
being identified and researched, studies are revealing that multiple phenotypes, based 






 Statistics show a dramatic increase in both the incidence and prevalence of EoE. A 
current study estimates the prevalence of pediatric EoE to be about 50 per 100,000 
children (Liacouras and Markowitz, 2012). One study states that the incidence of EoE 
has increased from 0.91 per 10,000 people in 2000 to 1.28 per 10,000 in 2003. 
Additionally, recent incident rates exceed those of inflammatory bowel disease in 
children (Delgado et. al, 2011). This striking increase in the diagnosis of EoE in the past 
five years brings to question whether this is a case of increased incidence or just of 
increased recognition as knowledge and appreciation of the disorder rises in the medical 
community (Center for Pediatric Eosinophilic Disorders, 2012). In one study, researchers 
reexamined esophageal biopsy specimens from 666 patients diagnosed with reflux 
esophagitis between 1982 and 1999. They found that EoE was present and had gone 
unrecognized in approximately 30% of patients (Delgado et. al, 2011). This suggests 
that the significant rise in incidence can be at least partially attributed to bias by 
increased recognition. 
 In children, EoE most often presents with susceptibility to other atopic disorders 
including food allergies, asthma, eczema, chronic rhinitis, and environmental allergies 
(Liacouras et. al, 2011). All large population-based case studies document that EoE is 
more predominant in males than in females; male predominance ranges from 70 to 92% 
(Liacouras and Markowitz, 2012). EoE can originate at any age, but often presents in 
childhood or in the third and fourth decades of life (Liacouras et. al, 2011). Average age 
of onset in children is between 6 to 10 years of age (Liacouras and Markowitz, 2012). It 
occurs in most races and ethnicities, though studies have reported highest prevalence in 
non-hispanic whites (Liacouras et. al, 2011). It affects children worldwide; cases have 
been found throughout the US and Canada and have been documented on all 
continents except Africa (Liacouras and Markowitz, 2012). A correlation with social 
  
 
economic status and possibility of seasonal variations is suspected but has not yet been 
systematically evaluated (Delgado et. al, 2011).  
 
Symptoms  
  EoE is characterized by symptoms related to esophageal dysfunction. In 
children, presentation is similar to that of Gastroesophageal Reflux Disease (GERD) 
(Liacouras, 2007). Infants may refuse to take a bottle, spit up frequently, and arch their 
back as a sign of pain (Center for Pediatric Eosinophilic Disorders, 2012). Infants may 
also present with chronic cough, feeding refusal, and slow weight gain or failure to thrive 
(7). Since GERD also presents with frequent vomiting and many of these same 
symptoms, it can be difficult to distinguish between severe GERD and EoE. Thus, 
infants can be the most challenging group in which to diagnose EoE (Center for Pediatric 
Eosinophilic Disorders, 2012). It should be noted that GERD is significantly more 
common than EoE, so it should still be the diagnosis considered first (“What is 
Eosinophilic Esophagitis?”, 2010). Children with EoE present most commonly with 
nausea, regurgitation, vomiting, abdominal pain, and difficulty swallowing (dysphagia). 
Older children may complain of heartburn, dysphagia, and food impaction (Center for 
Pediatric Eosinophilic Disorders, 2012).  
 Food refusal, oral aversion, vomiting, and poor weight gain are often found in 
children with EoE. Altered oral motor and sensory skills or a learned response to avoid 
eating may cause gagging and vomiting. Because of these behaviors, EoE can delay 
proper and timely development of age-appropriate oral motor skills and diet 
advancement. These feeding dysfunctions carry many nutrition implications, contributing 
to inadequate oral intake, resulting in malnutrition and inadequate growth (Mukkada et. 
al, 2010).  
  
 
 Additionally, about 50% of children diagnosed with EoE also show other allergic 
signs including asthma, allergic rhinitis, eczema, and environmental allergies (Liacouras, 
2007). Clinical recommendations include a thorough evaluation by an allergist to develop 
diagnosis and control concurrent atopic diseases (Liacouras et. al, 2011). 
 
Diagnosis  
 In 2007, experts in the GI and allergy fields released a consensus 
recommendation, providing guidelines for the diagnosis of EoE. Diagnosis requires both 
clinical and pathologic features; neither alone can confirm a diagnosis (Liacouras et. al, 
2011). If a child presents with suspect symptoms and the clinical evaluation points 
towards EoE, other possible causes of esophageal eosinophilia must first be excluded, 
particularly that of GERD. It is essential to trial the use of a proton pump inhibitor (PPI) in 
patients who have clinical symptoms of EoE to rule out GERD (Liacouras, 2007). A PPI 
is used in conjunction with an Esophagogastroduodenoscopy (EGD) to determine 
diagnosis. EGD with biopsy is the only test that can precisely determine the diagnosis of 
EoE (Liacouras et. al, 2011). No blood test or other non-invasive tests have yet been 
determined to accurately make a diagnosis. Thus, if clinical evaluation is suspect of EoE, 
physicians may take one of three routes towards diagnosis (Delgado et. al, 2011): 
• Immediate EGD followed by PPI for 8 weeks if the biopsies meet criteria, or 
• PPI for 8 weeks followed by EGD if symptoms persist, or 
• Immediate EGD followed by a dietary change without PPI if allergic phenotype is 
obvious and biopsies meet criteria 
 Recommendations state that two to four biopsy specimens of the proximal and 
distal esophagus should be obtained during the EGD. Additionally, biopsy specimens 
should be taken once of the gastric antrum and duodenum to exclude other potential 
causes of esophageal eosinophilia (Liacouras et. al, 2011). Other causes that must be 
  
 
ruled out include Celiac disease, Crohn’s disease, ulcerative colitis, eosinophilic 
gastroenteritis, and parasitic diseases (Delgado et. al, 2011). Histopathologial guidelines 
state that 1 or more biopsy specimens must show eosinophil infiltration and 
inflammation. The minimum threshold of eosinophils considered for diagnosis requires 
15 or more eosinophils per high-powered field (hpf) (Liacouras et. al, 2011).   
 As the diagnosis of EoE is being made with increasing frequency and as 
researchers learn more about the disorder, a number of limitations to these diagnostic 
criteria have been recognized. A 2011 review by a panel of 33 physicians with expertise 
in pediatric and adult allergy/immunology, gastroenterology, and pathology conducted a 
systematic review of all EoE publications since 2007 and found a number of problems 
with the current diagnostic criteria for EoE (Liacouras et. al, 2011). First, clinical 
diagnosis requires eliminating GERD as a potential cause of esophageal eosinophilia, 
but studies now show that there is a potential phenoptype of EoE that is PPI-responsive. 
In the 2011 consensus report, Liacouras et al. reported that a subgroup of patients has 
been recognized who present with typical EoE symptoms, have GERD diagnostically 
excluded, but demonstrate response to a PPI. The authors describe these patients as 
PPI-responsive esophageal eosinophilia. Thus, diagnosis excluding patients who 
respond to a PPI may not be sensitive enough to identify all phenotypes of EoE. The 
authors state that a validated assessment tool based on symptoms that can discriminate 
EoE from other diseases is urgently needed (Liacouras et. al, 2011).  
 An additional inherent problem with the present diagnostic criteria and definition of 
eosinophil-predominant infiltration lies within the required 15 or more eosinophils per hpf 
in an esophageal biopsy. First, the actual size of an hpf is variable depending on 
microscope used and is frequently not reported in many studies (Liacouras et. al, 2011). 
Thus, 15 eosinophils found in differing sizes of hpf may not hold significance. A 
standardized size of an hpf is necessary to compare data between different studies. 
  
 
Also, the number 15 carries no power to differentiate EoE with specificity and sensitivity 
from other esophageal diseases. One study reported a lack of correlation between peak 
eosinophil counts in esophageal biopsies and symptoms in untreated patients. Thus, 
prospective studies are needed to better define histological features than can 
differentiate EoE from other causes of esophageal eosinophilia. Liacouras suggests that 
studies should address the optimal number of tissues to biopsy, the anatomic location 
(proximal/middle/distal) most likely to correlate with diagnosis, and the best method to 
quantify eosinophils (Liacouras et. al, 2011). 
 
Relationship between EoE and GERD 
 EoE is a newly distinguished disease that clinically mimics GERD (Delgado et. al, 
2011). Prior to 1995, eosinophils present in the esophagus were characterized as 
GERD. A study by Kelly in 1995 was the first to report on a group of children with 
esophageal eosinophiliia that did not respond to anti-reflux therapy but did respond to an 
amino-acid based formula (Liacouras and Markowitz, 2012). Research has since proven 
that EoE is distinct from, but may coexist with, GERD. The Children’s Hospital of 
Philadelphia (CHOP) estimates that up to 10% of children with reflux also have EoE 
(Center for Pediatric Eosinophilic Disorders, 2012). Although there can be overlap in 
presence of the two diagnoses, there are a number of differences. First, EoE is 
characterized by male predominance and patients are more likely to present with 
dysphagia than those with GERD. EoE children are also more likely to be atopic patients 
and to fail anti-reflux therapy. Finally, EoE is more likely to start after 6 months of age, 





 The goals of treatment for EoE are resolution of symptoms, normal esophageal 
histology found with EGD, and the prevention of complications. These complications 
include chronic dysphagia and remodeling of the esophagus resulting in thickened and 
furrowed esophagus, mucosal tears, or proximal esophageal stricture. Treatment of EoE 
includes nutrition therapy and pharmacological therapy as described in detail below 
(Delgado et. al, 2011). 
 
Nutrition Therapy 
 The main goal of nutrition therapy is to remove the antigens causing inflammation 
in the esophagus while continuing to provide adequate nutrition to optimize growth and 
support development. Any macro and/or micronutrient deficiencies should be identified 
and corrected. Finally, the association between each food antigen and eosinophilic 
infiltration should be identified through single food reintroduction (Delgado et. al, 2011).  
 Two types of nutrition therapy exist: elemental diet therapy and an elimination diet. 
In an elemental diet, a 100% free amino acid based formula is used to meet 100% of 
estimated nutrition needs. Neocate, Neocate Jr., Elecare, and Elecare Jr. are 
hypoallergenic formulas commonly used for elemental diet therapy in infants and 
children. A major advantage of elemental diet therapy is that a significant response is 
seen within a short time of initiation. Reliance on formula also provides a complete 
source of nutrition, vitamins, and minerals without concern that the child is missing key 
nutrients by eliminating food from his diet. Because of this, use of tube feedings can 
reduce anxiety of parents and caretakers over the child’s inadequate intake. 
Disadvantages include expensive cost and difficulties with insurance coverage. 
Elemental formulas are not available in the grocery store, and so have more limited 
availability than standard formulas. Elemental formulas can be less appealing to a child 
because they are less palatable than standard formulas, due to their amino acid content 
  
 
versus whole proteins. Furthermore, use of formula to meet 100% of estimated nutrition 
needs introduces the possible need for a nasogastric or gastrostomy feeding tube. 
Finally, reliance on formula for 100% of nutrition needs holds the potential for delay in 
child development of feeding skills and for food aversion (Delgado et. al, 2011). 
 An elimination diet removes of a variable number of foods from the diet, either in 
a directed or non-directed manner. A directed elimination diet eliminates foods from the 
diet based on diagnostic allergy testing. Skin prick testing (SPT) and serum food-specific 
IgE levels are used to identify foods that are IgE mediated and cause an immediate 
reaction. Atopy patch tests (APT) identify foods that cause a delayed onset of symptoms 
(Liacouras et. al, 2011). A non-directed elimination diet is based on eliminating the most 
likely food antigens. The top foods most likely to cause an allergic response are milk, 
soy, egg, wheat, peanuts/tree nuts, and fish/shellfish (Delgado et. al, 2011). Other foods 
that are common causes and often excluded are corn, beef, and chicken. Advantages of 
an elimination diet are ease of implementation in comparison to an elemental diet, lower 
cost compared to purchasing formula, ease of food reintroduction, and the ability to 
continue to offer most foods. A major disadvantage of an elimination diet is the risk for 
nutritional deficiencies due to entire food elimination. As the number and types of foods 
removed from the diet increases, so does the risk of nutritional deficiencies. 
Disadvantages also include poor compliance, unnecessary elimination of foods, and 
failure to remove an unrecognized food from the diet (Delgado et. al, 2011). One 
challenge of dietary management of EoE is that no standard approach for food antigen 
restriction currently exists. Though there are many possible elimination diet strategies as 
described, the optimal and most effective method of identifying reactive foods remains 
unclear. In a comparison of the effectiveness of elimination diets based on SPT and ATP 
results, serum IgE levels, and removal of most common allergens without confirmation 
by allergy testing, all variations of elimination diets led to resolution of esophageal 
  
 
eosinophilia in a similar proportion of patients. Thus, the different methods appear to 
have equal success in identifying reactive foods in the pediatric population. An 
advantage of allergy testing is that fewer foods have to be removed from the diet when 
compared to empiric diets that remove entire food groups (Spergel et. al, 2012). Thus, 
the family and physician must weigh the ease of implementation and compliance to 




 Pharmacological management uses corticosteroids to manage symptoms of EoE. 
Corticosteroids function to reduce eosinophils through the induction of apoptosis, down-
regulation of chemotactic factors, and the inhibition of pro-inflammatory mediators 
(Liacouras and Markowitz, 2012). Systemic corticosteroids were the first medical 
treatment effective in improving both symptoms and histology in EoE patients 
(Liacouras, 2007). However, long-term use of systemic steroids is associated with risk of 
growth abnormalities, bone density loss, and mood disturbances. Thus, systemic 
corticosteroids are not recommended for long-term use and are only appropriate for 
symptom treatment in urgent cases (Liacouras and Markowitz, 2012). 
 Topical steroids are the current standard of care for pharmacologic treatment of 
EoE. Topical steroids are not associated with systemic absorption and have significantly 
fewer side effects than systemic steroids. Esophageal candidiasis, or thrush, and dry 
mouth are the most commonly reported side effects of topical oral steroids. They are 
prescribed to be sprayed into the pharynx and swallowed before eating to topically coat 
the esophagus and reduce inflammation. Initial dose varies from 110 to 880 µg twice per 




 Clinical cases show that corticosteroids are extremely effective in symptom and 
histologic remission. One study documented that greater than 95% of children reached 
remission within 4 weeks of treatment. However, symptoms typically recur in about 90% 
of patients upon discontinuation of corticosteroids. Therefore, the majority of patients 
require chronic use for maintenance therapy (Liacouras and Markowitz, 2012). 
 
Prognosis  
 Spontaneous remission of EoE is rare. However, inflammation and its symptoms 
can be controlled with consistent nutrition and pharmacological therapy for most 
individuals (Liacouras and Markowitz, 2012). Since EoE is a newly recognized disease, 
little is known about the prognosis for children with this diagnosis. It may be possible that 
some children fully outgrow EoE similar to how they outgrow other allergies. It also may 
be possible that the number of foods that trigger eosiniphilic infiltration decreases over 
time; or that a child does not outgrow the disease at all (Center for Pediatric Eosinophilic 
Disorders, 2012). Further research is needed to better define the prognosis for children 
with EoE.  
  
 
Case Presentation: Description of the patient  
 
 J.A. is a 5 year and 6 month old white male. He was born a healthy full term infant 
(40 weeks gestation) at 7.2 pounds and 21” at birth. J.A. was diagnosed with EoE at 19 
months of age.  
Past Medical History: 
1. Eosinophilic Esopgagitis (EoE) 
2. History of (H/o) failure to thrive (FTT) 
3. Peanut allergy 
 
Family Medical History: Father has significant GERD and is treated with Nexium. He is 
allergic to molds and has rheumatoid arthritis. Mother has periodic epigastric pain that 
  
 
she treats with a PPI. She has a history of anxiety, seasonal and cat allergies. Jake’s 
grandmother has a history of lymphoma.  
Social History: J.A. is an only child. Mother is a teacher and father is a mechanic. 
Medications: Prevacid 15 mg twice per day, Pulmicort 0.5 mg 
Diagnosis: NC1.4: Altered gastrointestinal (GI) function related to Eosinophilic 
Esophagitis as evidenced by need for a gastrostomy tube (G-tube), oral steroids, and 
frequent endoscopies to ensure adequate nutrition and growth. 
 
Review of the course of the patient 
 
 At 18 months of age, J.A. presented with acute febrile illness with a fever of 102-
103ºF, lethargy, upper respiratory infection symptoms, and nasal congestion. His fever 
continued for about 1.5 weeks. During this illness, J.A. lost significant weight, causing 
his parents to be more aware of his general disinterest in eating. His parents reported 
that he would push his jaw forward continuously as if his throat hurt or itched and that he 
began to pat his chest and whine and occasionally throw up after eating a few bites of 
food.  
 J.A. was initially diagnosed with FTT and feeding difficulties. The physician gave 
antibiotics to clear the fever, which was suspected to be secondary to a case of 
cytomegalovirus. Attending physician also reported “cheesy” fluid at the back of J.A.’s 
throat and noted him to be pale and edematous with a waxy appearance to his skin. 
After this visit, J.A. was admitted as an inpatient at UNC hospitals due to his fever and 
acute condition.  
 Endoscopy during hospital admission demonstrated findings consistent with 
severe EoE, > 120 eosinophils/hpf in esophagus. Attending physician assessment 
concluded patient to have eosinophilic esophagitis with a likely secondary 
immunodeficiency. Medications included Prevacid, and Pulmicort. Prevacid is a PPI 
  
 
used to treat reflux, and Pulmicort is an oral corticosteroid used to treat eosinophilic 
inflammation. G-tube was placed for feeding and elemental diet was started. 
 
 
Lab J.A.’s value Normal limits Significance 
Eosinophils/hpf 120 0 >15/hpf considered 
for diagnosis of EoE 
Plasma eosinophils 3.4% 0-3% Peripheral eosinphilia 




Nutritional Assessment and Intervention  
 
 J.A. had a strong history of emesis and loss of appetite prior to diagnosis and 
hospitalization. He was breastfed until 1 year of age, with solid foods started at 6 months 
of age. At about 15 months, he began to have emesis with feedings. His parents noticed 
that when they gave him a bottle to go to sleep, he would take the bottle but then throw it 
up. They began propping him with his head elevated, which slightly improved the 
vomiting. About the same time the emesis started, they noticed he began to take less 
solid food and focus more on liquids. His oral intake decreased to taking only 1 chicken 
nugget or a few bites of another meat, and then only milk for the rest of the day. At 15 
months, J.A. was given peanut butter for the first time. After an hour, he developed 
periorbital edema and itchy rash, hives and tongue swelling. A peanut allergy was 
confirmed by skin testing through UNC Pediatric Allergy and Immunology and the family 
has since avoided peanuts and peanut products.  
 At initial time of diagnosis and initiation of treatment, J.A. weighed 9.49 Kg (<3rd 
percentile), height was 75 cm (<3rd percentile), and his head circumference was 45.9 cm 
(~7th percentile). 24 hour recall reported that he took 30 ounces of whole milk, one 
drinkable yogurt, and about 300 calories of solid foods (cheerios, meats, and small 
amounts of other table foods) per day. His dietitian estimated that this provided J.A. with 
  
 
about 700 calories (70 calories/Kg) and 13-16 grams protein (1.5 grams/Kg) per day. His 
nutrition needs were estimated to be 98 Kcal/Kg, 1.6-2 Gm protein/Kg, and 100 mL 
fluid/Kg. The goal was for J.A. to meet weight gain velocity of 10-15 Gm/day. 
 J.A. was started on continuous tube feeds of Elecare @ 57 mL/hr via Gtube to 
provide 97 Kcal/Kg and 2.9 Gm/Kg per day. Elecare is a 100% amino acid based 
(versus an intact hydrolyzed protein), hypoallergenic formula commonly used for infants 
and children with severe food allergies and various GI disorders (Help for Children with 
Food Allergies, 2012).  
Elecare can be used for dietary management of: 
- Severe food allergies 
- Eosinophilic gastrointestinal disorders 
- Short bowel syndrome 
- Chronic diarrhea 
- Malabsorption 
- Dietary protein enterocolitis  
 
In J.A.’s case, his parents choose to go the route of an elemental diet for a number of 
reasons. First, because of his already compromised nutrition status, they would not have 
to worry whether he was meeting his nutritional needs through an elimination diet. 
Second, because of the severe condition of his disorder, he did not have adequate 
feeding skills or willingness to take what he needed for growth by mouth. Thus, an 
elemental formula was initially given to meet 100% of J.A.’s needs.  
 
Food Reintroduction 
 Once symptom and histologic resolution has been achieved through diet and 
pharmacological therapy, foods can be reintroduced back into the child’s diet. The 
Children’s Hospital of Philadelphia (CHOP) is a leader in the area of EoE and has a 
general protocol used for reintroduction of foods following an elemental diet (see 
appendix A) (Center for Pediatric Eosinophilic Disorders, 2012). Foods are group based 
on allergic associations, from least allergic (group A) to most allergic (group D). Patients 
  
 
start by reintroducing foods from group A first and move to group B, C, and then D. One 
new food is offered for seven days, offered every day to expose the child to the antigen. 
Repeat EGDs are done every 6-8 weeks and the process continues until a positive 
biopsy occurs. The foods that appear to cause abnormal biopsies are removed 
indefinitely from the child’s diet (Liacouras and Markowitz, 2012). 
 J.A.’s family generally followed the CHOP guidelines to introduce foods to his diet. 
Eosinophils dropped to within normal limits and were not detected in the esophagus 
within 4 weeks of being on an elemental diet. Mom called Elecare a “miracle for him”. 
The family did take some liberties to focus on foods that they already knew he liked, in 
order to encourage increased consumption. J.A. underwent EGDs every six weeks, with 
the addition of three new foods between each scope and biopsy. Appendix B describes 
a table of food introductions and scope/biopsy results for J.A. over a 2 year period. 
About 2 years later, J.A.'s physician tried reducing doses of Pulmicort, only to see 
peripheral eosinophil count to rise in the next scope. The medication was returned to its 
standard doses, confirming the need for long-term use of medication for maintenance 
therapy. 
 
Progressive description of dietary management 
 From the nutrition perspective, our primary concern is for J.A. to achieve catch-up 
growth and to reach a point where he can meet his estimated needs and continue to 
support weight gain through a solely oral diet. As J.A. progressed with food 
reintroduction, tube feed regimen was slowly weaned. Six months status post-diagnosis, 
Elecare was reduced to 700 mL overnight and three 100 mL boluses during the day 
(1000 mL total). One year status post-diagnosis, Elecare was reduced to 750 mL/day. At 
this time, J.A. had begun to take one EO28 Splash per day (250 Kcal, 8 Gm protein 
each), an amino acid based juice oral nutrition supplement. Thirty months status post-
  
 
diagnosis, Elecare was reduced to 300 mL overnight. Estimated oral intake was about 
1000 calories (2 EO28 Splash in addition to 500-600 calories from food). Nearly three 
years status post-diagnosis, Elecare was discontinued.  
 J.A.’s growth charts (see Appendix C) illustrate classical catch-up growth followed 
by weight maintenance. He presented below the 3rd percentile for weight for age, 
reached the 25th percentile 5 months after G-tube placement, and has held steady at the 
25th percentile even after G-tube was removed. He presented below the 3rd percentile for 
length for age, reached the 10th percentile 5 months after initiation of treatment, and has 
held stead. Finally, weight for length has remained steady around the 50th percentile. RD 
is continuing to monitor adequacy of solely po diet to meet estimated nutrition needs and 
for continued adequate weight gain.  
 
Other treatments received by the patient 
 
 J.A. also received feeding therapy and speech therapy throughout the course of his 
treatment. The use of tube feeding and the need for a liquid elemental formula can delay 
development of oral feeding skills due to delay in introduction of solids and textures 
(Liacouras and Markowitz, 2012). This makes feeding therapy important to aid in catch 
up development when diet allows. His mom described feeding therapy as “not pleasant”. 
A speech therapist also worked with J.A. on strengthening the muscles usually made 
stronger through chewing, for speech and articulation. 
 
Prognosis and Discussion 
 J.A’s G-tube was removed 3 years and 9 months status post-diagnosis. He has 
been able to support adequate weight gain and growth with solely po diet. His diet has 
expanded to include most foods (except nuts and milk). He has completed his work with 
the speech therapist and feeding therapist and Mom reports that he is no longer a picky 
  
 
eater. J.A. is currently in kindergarten; Mom reports he is doing great and shows even 
more interest in food now that the G-tube is not in place.  
 Pulmicort has been successful at keeping J.A.’s symptoms at bay. He will remain 
on Pulmicort, however the side effects of long-term use are not known. One option is to 
take him off of Pulmicort and do allergy testing to find out his true allergies. This is risky 
because J.A.’s symptoms are likely to return during this time period. It would also put 
him through another time period of frequent EGDs, other testing, and possible illness, 
which his parents are hesitant to do at this time. Until they decide to do more extensive 
testing, J.A. will remain on Pulmicort and continue to avoid nuts and milk. 
 One concern that was not addressed in this case was to ensure that J.A. was 
receiving a multivitamin. To my knowledge, he was not. While meeting his estimated 
needs with Elecare, his micronutrient needs were met. However, we need to ensure that 
he continues to meet vitamin and mineral needs after he is weaned off the nutritionally 
complete elemental formula, particularly given his history of FTT and goals for catch-up 
growth. I would recommend Animal Parade Children’s Liquid Multivitamin and Mineral, a 
hypoallergenic supplement appropriate for use in children with food allergies. 
 J.A.’s treatment overall was very successful at meeting the goals of therapy over 
the course of over 2 years: resolution of symptoms, normal esophageal histology found 
via EGD, and the prevention of complications. The family and physicians followed the 
CHOP guidelines for food reintroduction very closely, while an RD monitored for dietary 
adequacy and used tube feeds to meet estimated needs that he was not meeting by 
mouth. Together, the team got his weight and growth back on track. 
 Future research is needed for prospective therapies that do not rely on 
chronic use of steroids. IL-5 is known to promote eosinophil trafficking to the 
esophagus, growth, activation, and survival (Stein et. al, 2006). In clinical trials in 
patients with severe asthma associated with eosinophilia, anti-IL-5 therapy has 
  
 
demonstrated significant reduction in asthma symptoms. To date, there have 
been no large trials for anti-IL5 therapy in EoE, but smaller clinical trials have not 
shown conclusive evidence of depleting eosinophil counts. Studies show partial 
reduction in esosinophils, but it remains unknown if full depletion and remission 
of symptoms is possible and safe with anti-IL5 therapy (Corren, 2012). If a new 
large scale clinical trial is undertaken, J.A. may be a good candidate for anti-IL5 
therapy. 
 Physicians, dietitians, and other medical professionals can gain knowledge 
from this experience with classical patients like J.A. who have successfully 
achieved control of their disease through a concerted effort by family, physician 
and RD. As EoE is becoming more prevalent and increasingly recognized in the 
pediatric population, dietitians must be aware of the best options for nutrition 
therapy and the advantages and disadvantages of each option. Dietitians should 
keep up-to-date with the growing collection of literature on the etiology and risk 
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Appendix A: CHOP’s Food Reintroduction Guidelines 
 
The Children’s Hospital of Philadelphia 
Center for Pediatric Eosinophilic Disorders 
DIVISION OF ALLERGY AND IMMUNOLOGY 
Richard D. Wood Center, 5th Floor 
www.chop.edu 
 
FOOD INTRODUCTION FOLLOWING AN ELEMENTAL DIET 
The following list is a general guideline for the reintroduction of foods after your 
elemental diet.  
Specific changes may be required depending on individual allergies and/or intolerances. 
You will need to remain on your elemental formula in the early stages of food re-
introduction to make sure you receive adequate calories, protein, vitamins and minerals. 
 
Points to remember: 
1. You and your doctor will decide which foods are safe to try and how many foods 
you will add. You will usually start with foods from columns A and B, as these are 
less likely to cause a reaction. 
2. Each food should be introduced for a minimum of 7 days before progressing to 
the next food.  
3. Report any suspected reaction to your doctor before proceeding to the next food. 
You should omit any foods which have caused symptoms or for which you have 














Grapes, pear, peaches, 
plum, apricot, cherries 
orange, grapefruit, 


























































Appendix B: Jake’s Scope History 
 
Scope Date Age Esophagus 
EOS 
FOODS introduced prior to scope 
Diagnosis 19 months 120 Open diet 
+ 8 weeks 21 months 0 Green beans, apples 
+ 6 weeks 22 months 0 Turkey, carrots, oranges 
+ 6 weeks 2 years 0 Rice, potato, bananas 
+ 6 weeks  0 Peaches, blueberries, corn, beef 
+ 6 weeks  0 Pork, pinto beans, strawberries 
+ 6 weeks  0 No new foods 
+ 6 weeks 2 years and 
6 months 
0 Tomato, chicken, black beans, 
raisins/grapes 
+ 6 weeks  
 
(1 year s/p 
diagnosis) 
0 No new foods introduced 
+6 weeks  0 Wheat, lemon, lime 
+ 6 weeks  0 Soy, plums 
+ 6 weeks 3 years 0 Eggs, cherry 
+ 6 weeks  0 Eggs removed 
+ 6 weeks  0 All foods (no milk/nuts) 
+ 4 months  
 
(2 years s/p 
diagnosis) 
0 Pulmicort reduced to 1x per day 



























Appendix C: J.A’s Growth Charts (Birth through 36 months) 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
